This invention provides a series of new oxindole derivatives 1-21, evaluated for their antiglycation potential by using in vitro BSA-MG glycation model. These derivatives showed a varying degree of antiglycation activity with IC
50
values ranging between 150-856 μM. Compound 14 (IC
50
=150.4±2.5 μM) was found to be the most potent among all derivatives, even better than the standard inhibitor i.e. rutin (IC
50
=294.5±1.50 followed by compounds 13 and 8 with IC
50
value of 194.40±2.5 and 211.41±4.1 μM, respectively.